3Daughters Named “Startup of the Year” at BioLabs Philadelphia Investor Day 2024
April 19 2024 - 8:00AM
3Daughters, Inc., a clinical development company fueling
evolutionary healthcare for women, was voted the “Startup of Year”
by top life science investors and venture capitalists at the 2024
BioLabs Investor Day that took place in Philadelphia on April 16,
2024.
BioLabs Investor Day events are carefully curated, invite-only
pitch events where top startups are connected directly with major
investors from across the eastern seaboard. Out of 78 applications
submitted, 3Daughters was one of 15 companies selected to pitch at
the event. Following a competitive pitch process, participating
investors anonymously selected 3Daughters as the “Startup of The
Year” for 2024.
3Daughters is addressing the needs of women who use birth
control on average for 30 years of their lives with a novel,
frameless, and sophisticated non-hormonal intrauterine device (IUD)
for long-acting contraception. The innovation behind 3D-001,
3Daughters’ lead asset, is a marked departure from the current
plastic T-shaped framed IUD, which is widely known to cause
significant insertion pain. With 3D-001 and the Company’s patented
Slider™ for insertion and retrieval, 3Daughters will eliminate the
most painful steps for IUD insertion, which prevent women from
getting one of the most effective forms of birth control.
“It’s a privilege and honor for 3Daughters to be recognized as
the ‘Startup of the Year’ by BioLabs and investors in the life
science community. Selected from the great group of emerging
companies that presented, this award stands out as an endorsement
for Women’s Health and the need for innovation in the space. This
recognition further fuels our commitment to bring our game-changing
IUD into clinic next year,” commented Mary Beth Cicero, CEO of
3Daughters.
3Daughters is launching a Series A financing round of $15M that
will fund 3D-001’s Phase 1 study that will provide critical data
relating to pain and ease of insertion. With copper as the active
ingredient and proven spermicide, the regulatory pathway has been
confirmed as a 505(b)(2) relying on the FDA’s findings of safety
and efficacy. As a non-hormonal contraceptive option, 3Daughters
will be addressing the needs of women who are looking for a highly
effective and long-term contraceptive without exposure to hormones
that addresses the insertion pain, and without the strings T-shaped
IUD’s need for removal.
“Thank you to BioLabs and the sponsors of this event for the
chance to tell the 3Daughters story. We are well aware of pain
women endure when they opt for the current IUD’s on the market. The
attention from awards like the BioLabs Investor Day will help to
heighten investor interest in supporting our clinical program and
others to foster a better future for women’s health products – a
sector poised to exceed $30 billion by the end of the decade,”
concluded Mary Beth Cicero, CEO of 3Daughters.
The award from BioLabs totaling over $20,000 includes cash,
credits, resources, and services across various operational aspects
that are essential to success of an emerging life science
company.
About BioLabs
Biolabs' mission is to empower entrepreneurs and drive life
science innovation worldwide. BioLabs’ comprehensive innovation
support platform provides entrepreneurs access to premium,
fully-equipped co-working lab and office facilities, extensive
educational programming, a supportive community and connections to
a global network of fellow entrepreneurs, collaborators, and
capital partners. Currently operating in 15 locations across the
US, Europe and Japan, BioLabs accelerates the pace of innovation
commercialization by enabling entrepreneurs to focus on science,
not operations. This is the 8th Investor Day held by BioLabs
worldwide, and the second annual Investor Day at the Philadelphia
location.
About 3DaughtersTM
3Daughters is a clinical development company focused on
evolutionary healthcare for women where cutting-edge research and
innovation is desperately needed. The Company’s technology platform
is based on physics and geometry to deliver targeted therapy to the
uterus. The first product, (3D-001), is a frameless, magnetic,
non-hormonal intrauterine device (IUD) for long-acting
contraception that conforms to a woman’s body. Combined with our
unique, patented Slider™ system (for insertion and retrieval), we
will eliminate the most painful steps in the insertion process as
well as the nuisance factor of strings (needed for removal).
3Daughters’ vision is to solve health issues for women,
particularly significant, and neglected, problems. 3Daughters plans
to radically disrupt the IUD market by addressing the major
adoption barrier — insertion pain. This pain is associated with all
current rigid, plastic T-shape framed IUDs on the market and
prevents women from selecting one of the most effective forms of
birth control. Visit 3daughtershealth.com for more
information.
Contact:Louis ScottiSenior Vice President, Business Operations
& Corporate Developmentlscotti@3daughtershealth.com